174 related articles for article (PubMed ID: 35255445)
1. Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials.
Nassif EF; Blay JY; Massard C; Dufresne A; Brahmi M; Cassier P; Ray-Coquard I; Pautier P; Leary A; Sunyach MP; Bahleda R; Levy A; Le Pechoux C; Honoré C; Mir O; Le Cesne A
ESMO Open; 2022 Apr; 7(2):100425. PubMed ID: 35255445
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential.
Francis P; Namløs HM; Müller C; Edén P; Fernebro J; Berner JM; Bjerkehagen B; Akerman M; Bendahl PO; Isinger A; Rydholm A; Myklebost O; Nilbert M
BMC Genomics; 2007 Mar; 8():73. PubMed ID: 17359542
[TBL] [Abstract][Full Text] [Related]
4. Managing patients with advanced soft tissue sarcoma: Evolving landscape from an Australian perspective.
Bae S; Brnabic A; Crowe P; Carey-Smith R; Andelkovic V; Singhal N; Stalley P; Yip D; Desai J
Asia Pac J Clin Oncol; 2022 Dec; 18(6):605-613. PubMed ID: 35098667
[TBL] [Abstract][Full Text] [Related]
5. New benchmarks to design clinical trials with advanced or metastatic liposarcoma or synovial sarcoma patients: An EORTC - Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis based on a literature review for soft-tissue sarcomas.
Kantidakis G; Litière S; Neven A; Vinches M; Judson I; Blay JY; Wardelmann E; Stacchiotti S; D'Ambrosio L; Marréaud S; van der Graaf WTA; Kasper B; Fiocco M; Gelderblom H
Eur J Cancer; 2022 Oct; 174():261-276. PubMed ID: 36116829
[TBL] [Abstract][Full Text] [Related]
6. Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Prognostic Markers for Extensive Disease of Small Cell Lung Cancer.
Minami S; Ihara S; Komuta K
World J Oncol; 2020 Jun; 11(3):98-105. PubMed ID: 32494316
[TBL] [Abstract][Full Text] [Related]
7. Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Biomarkers of Immune-Checkpoint Inhibitor for Non-Small Cell Lung Cancer.
Minami S; Ihara S; Ikuta S; Komuta K
World J Oncol; 2019 Apr; 10(2):90-100. PubMed ID: 31068989
[TBL] [Abstract][Full Text] [Related]
8. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.
Karavasilis V; Seddon BM; Ashley S; Al-Muderis O; Fisher C; Judson I
Cancer; 2008 Apr; 112(7):1585-91. PubMed ID: 18278813
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
D'Ambrosio L; Touati N; Blay JY; Grignani G; Flippot R; Czarnecka AM; Piperno-Neumann S; Martin-Broto J; Sanfilippo R; Katz D; Duffaud F; Vincenzi B; Stark DP; Mazzeo F; Tuchscherer A; Chevreau C; Sherriff J; Estival A; Litière S; Sents W; Ray-Coquard I; Tolomeo F; Le Cesne A; Rutkowski P; Stacchiotti S; Kasper B; Gelderblom H; Gronchi A;
Cancer; 2020 Jun; 126(11):2637-2647. PubMed ID: 32129883
[TBL] [Abstract][Full Text] [Related]
11. Analysis of clinical factors associated with survival in patients with soft-tissue sarcoma receiving trabectedin.
Simetić L; Blažičević K; Ladenhauser T; Golčić M; Majnarić T; Herceg D
Anticancer Drugs; 2021 Nov; 32(10):1058-1066. PubMed ID: 34232944
[TBL] [Abstract][Full Text] [Related]
12. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials.
Young RJ; Natukunda A; Litière S; Woll PJ; Wardelmann E; van der Graaf WT
Eur J Cancer; 2014 Dec; 50(18):3178-86. PubMed ID: 25459395
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of trabectedin for patients with unresectable and relapsed soft-tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study.
Kobayashi H; Iwata S; Wakamatsu T; Hayakawa K; Yonemoto T; Wasa J; Oka H; Ueda T; Tanaka S
Cancer; 2020 Mar; 126(6):1253-1263. PubMed ID: 31825533
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis.
Saerens M; Brusselaers N; Rottey S; Decruyenaere A; Creytens D; Lapeire L
Eur J Cancer; 2021 Jul; 152():165-182. PubMed ID: 34107450
[TBL] [Abstract][Full Text] [Related]
15. Histopathological re-classification of extremity pleomorphic soft tissue sarcoma has clinical relevance.
Massi D; Beltrami G; Capanna R; Franchi A
Eur J Surg Oncol; 2004 Dec; 30(10):1131-6. PubMed ID: 15522563
[TBL] [Abstract][Full Text] [Related]
16. Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy.
Bilen MA; Shabto JM; Martini DJ; Liu Y; Lewis C; Collins H; Akce M; Kissick H; Carthon BC; Shaib WL; Alese OB; Steuer CE; Wu C; Lawson DH; Kudchadkar R; Master VA; El-Rayes B; Ramalingam SS; Owonikoko TK; Harvey RD
BMC Cancer; 2019 Aug; 19(1):857. PubMed ID: 31464611
[TBL] [Abstract][Full Text] [Related]
17. TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities.
Koelsche C; Renner M; Hartmann W; Brandt R; Lehner B; Waldburger N; Alldinger I; Schmitt T; Egerer G; Penzel R; Wardelmann E; Schirmacher P; von Deimling A; Mechtersheimer G
J Exp Clin Cancer Res; 2014 Apr; 33(1):33. PubMed ID: 24726063
[TBL] [Abstract][Full Text] [Related]
18. Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy.
Santoro A; Comandone A; Basso U; Soto Parra H; De Sanctis R; Stroppa E; Marcon I; Giordano L; Lutman FR; Boglione A; Bertuzzi A
Ann Oncol; 2013 Apr; 24(4):1093-8. PubMed ID: 23230134
[TBL] [Abstract][Full Text] [Related]
19. PML expression in soft tissue sarcoma: prognostic and predictive value in alkylating agents/antracycline-based first line therapy.
Vincenzi B; Santini D; Schiavon G; Frezza AM; Silletta M; Crucitti P; Casali P; Dei Tos AP; Rossi S; Rizzo S; Badalamenti G; Tomasino RM; Russo A; Butrynski JE; Tonini G
J Cell Physiol; 2012 Apr; 227(4):1657-62. PubMed ID: 21678421
[TBL] [Abstract][Full Text] [Related]
20. Trabectedin in metastatic soft tissue sarcomas: Role of pretreatment and age.
Hoiczyk M; Grabellus F; Podleska L; Ahrens M; Schwindenhammer B; Taeger G; Pöttgen C; Schuler M; Bauer S
Int J Oncol; 2013 Jul; 43(1):23-8. PubMed ID: 23652821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
